Louise Rodino-Klapac, Ph.D.

Louise Rodino-Klapac, Ph.D.

President, Research and Development and Technical OperationsatSarepta Therapeutics· In proxies 2021–2025

Pay in FY2025+63% from the year before · Sarepta Therapeutics stock -82.3% the same year

Louise Rodino-Klapac, Ph.D. was paid $4.5M in FY2025 (Dec), up 63%. Sarepta Therapeutics stock fell 82.3% that year.

Pay$100 in the stock at the end of FY20 → $13
Pay is from the Summary Compensation Table of each Sarepta Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sarepta TherapeuticsPublic company · 5 yr
    • President, Research and Development and Technical Operations2021 – Present · 5 yrStock in role -89%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?